DMA Share Price

Open 0.17 Change Price %
High 0.17 1 Day -0.01 -5.88
Low 0.16 1 Week -0.01 -5.88
Close 0.16 1 Month 0.00 0.00
Volume 179943 1 Year -0.04 -20.00
52 Week High 0.35
52 Week Low 0.14
DMA Important Levels
Resistance 2 0.17
Resistance 1 0.17
Pivot 0.16
Support 1 0.15
Support 2 0.15
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
DVC-H 0.15 150.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
NQE 0.02 100.00%
NQE 0.02 100.00%
TYE 0.02 100.00%
BVQ 0.02 100.00%
MOO 0.02 100.00%
SRJ 0.02 100.00%
SRJ 0.02 100.00%
More..
CVE Canada Top Losers Stocks
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
IVI 0.02 -33.33%
RHA 0.02 -33.33%
More..

Diamedica Inc (CVE: DMA)

DMA Technical Analysis 5
As on 24th Jan 2017 DMA Share Price closed @ 0.16 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.21 & Strong Sell for SHORT-TERM with Stoploss of 0.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
DMA Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DMA Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.diamedica.com
DMA Address
DMA
One Carlson Parkway
Suite 124
Minneapolis, MN 55447
United States
Phone: 763-270-0603
DMA Latest News
Kabul nights   Satellite PR News (press release)   - 24th Dec 16
DiaMedica Announces Name Change to DiaMedica Therapeutics Inc.   EIN News (press release)   - 24th Dec 16
Form NSAR-A WESTERN ASSET HIGH INCOM For: Oct 31   StreetInsider.com   - 23rd Dec 16
Form 6-K TiGenix NV For: Dec 23   StreetInsider.com   - 23rd Dec 16
Form 4 VERINT SYSTEMS INC For: Dec 22 Filed by: FANTE PETER   StreetInsider.com   - 21st Dec 16
DiaMedica Announces Positive Top-Line Results from DM199 Bridging Clinical Trial   Marketwired (press release)   - 20th Dec 16
OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology   EIN News (press release)   - 12th Dec 16
Global Type 1 Diabetes (Juvenile Diabetes) Pipeline Report 2016 - Review of ...   Business Wire (press release)   - 08th Jul 16
Research and Markets: Acute Ischemic Stroke Pipeline Review, H2 2015 - 17 ...   Business Wire (press release)   - 02nd Sep 15
DiaMedica plunges as DM199 fails to improve glucose control in type 2 diabetes   Proactive Investors USA & Canada   - 18th Nov 14
Interactive Technical Analysis Chart Diamedica Inc ( DMA CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Diamedica Inc
DMA Business Profile
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company’s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.